Is VOYAGER THERAPEUTICS INC (NASDAQ:VYGR) suited for growth investing?

Growth investors are looking for stocks showing high revenue and EPS growth. We will have a look here to see if VOYAGER THERAPEUTICS INC (NASDAQ:VYGR) is suited for growth investing. Investors should of course do their own research, but we spotted VOYAGER THERAPEUTICS INC showing up in our Louis Navellier growth screen, so it may be worth spending some more time on it.

Key Considerations for Growth Investors.

• VOYAGER THERAPEUTICS INC has achieved an impressive Return on Equity (ROE) of 55.98%, showcasing its ability to generate favorable returns for shareholders.
• VOYAGER THERAPEUTICS INC has consistently exceeded EPS estimates in the last 4 quarters, demonstrating its ability to outperform market expectations. This trend highlights the company's strong financial performance and its potential for future growth.
• With impressive 1-year revenue growth of 510.0%, VOYAGER THERAPEUTICS INC showcases its ability to generate increased sales and revenue. This growth highlights the company's strong customer demand and its effective business strategies.
• VOYAGER THERAPEUTICS INC has experienced 6.0K% q2q revenue growth, indicating a significant sales increase.
• With positive growth in its operating margin over the past year, VOYAGER THERAPEUTICS INC showcases its ability to improve profitability through effective cost control and operational efficiency. This growth underscores the company's commitment to enhancing its financial performance.
• The free cash flow (FCF) of VOYAGER THERAPEUTICS INC has seen steady growth over the past year, indicating enhanced cash flow generation and financial health. This trend underscores the company's effective capital management and its ability to generate sustainable cash flows.
• The earnings per share (EPS) of VOYAGER THERAPEUTICS INC have shown positive growth on a quarter-to-quarter (Q2Q) basis, with a 305.0% increase. This reflects the company's ability to improve its profitability over time.
• Over the past 3 months, analysts have adjusted their EPS Estimate for VOYAGER THERAPEUTICS INC with a 34.33% change. This highlights the evolving outlook on the company's EPS potential.
• The quarterly earnings of VOYAGER THERAPEUTICS INC have shown a 305.0% increase compared to the previous quarter, as revealed in the recent financial report. This growth signifies positive momentum in the company's financials, pointing towards a promising upward trend
• The earnings per share (EPS) growth of VOYAGER THERAPEUTICS INC are accelerating: the current Q2Q growth of 305.0% is above the previous year Q2Q growth of -507.0%. Earnings momentum and acceleration are key for high growth systems.

Fundamental analysis of NASDAQ:VYGR

ChartMill utilizes a proprietary algorithm to assign a Fundamental Rating to every stock. This rating, ranging from 0 to 10, is computed daily by analyzing a variety of fundamental indicators and properties.

VYGR gets a fundamental rating of 6 out of 10. The analysis compared the fundamentals against 588 industry peers in the Biotechnology industry. VYGR has an excellent financial health rating, but there are some minor concerns on its profitability. VYGR has a correct valuation and a medium growth rate.

Check the latest full fundamental report of VYGR for a complete fundamental analysis.

Our Lois Navellier screen will find you more ideas suited for growth investing.

Disclaimer

This article should in no way be interpreted as advice in any way. The article is based on the observed metrics at the time of writing, but you should always make your own analysis and trade or invest at your own responsibility.